Overview

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

Status:
Completed
Trial end date:
2021-04-21
Target enrollment:
Participant gender:
Summary
The study will examine the impact on cognitive reserve of a pharmacist-physician patient-centered medication therapy management intervention to address inappropriate medication use as identified by the Beers 2015 list. By bolstering cognitive reserve, this project will directly address the National Alzheimer's Project Act 2015 priorities serving to delay onset of symptoms in preclinical dementia. The results of this study will provide valuable insights on how to expand this intervention to reduce the prevalence and associated healthcare costs of symptomatic Alzheimer's disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Daniela Moga
Collaborator:
National Institute on Aging (NIA)
Treatments:
Butylscopolammonium Bromide
Scopolamine
Scopolamine Hydrobromide